MSR1 and lymphoma: Kawajiri and colleagues reported that a high number of CD204+ TAMs was associated with poorer 3-year overall survival (OS) and cumulative incidences of relapse, and a poorer prognosis in allogeneic hematopoietic cell transplantation for malignant lymphomas, such as T-cell lymphoma and leukemia (68).